SABRE: A New Era for Osteoporosis Trials
Échec de l'ajout au panier.
Veuillez réessayer plus tard
Échec de l'ajout à la liste d'envies.
Veuillez réessayer plus tard
Échec de la suppression de la liste d’envies.
Veuillez réessayer plus tard
Échec du suivi du balado
Ne plus suivre le balado a échoué
SABRE: A New Era for Osteoporosis Trials
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
The lads sit down with Mary Bouxsein to explore SABRE — the landmark project aiming to make BMD a validated regulatory endpoint in osteoporosis trials. Mary walks us through how her team brought together data from more than 160,000 patients, why this could transform the speed and ethics of future drug development, and what it means for equity and patient care. A big conversation with one of the true leaders in the field — and a glimpse into a future where better treatments reach people faster.
Mary Bouxsein is the Maurice E. Mueller Professor of Orthopedic Surgery at Harvard Med School and Co-lead of the Study to Advance BMD as a Regulatory Endpoint (SABRE).
Pas encore de commentaire